'Brain tumor' may be the two most frightening words a patient will ever hear a surgeon speak. After the shock, there will be questions--most will ask what can be done.
In mid-December, the U.S. Food & Drug Administration announced approval of Luxturna (voretigene neparvovec-rzyl), the first directly administered gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene ... in this case, a rare form of inherited vision loss.
"It's potentially revolutionary," says Luciano Costa, MD, PhD, about chimeric antigen receptor (CAR) T-cell therapy -- a newly approved gene therapy for blood cancers.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: